<HashMap><database>EGA</database><scores/><additional><omics_type>Genomics</omics_type><dataset_type>N/A</dataset_type><full_dataset_link>https://ega-archive.org/datasets/EGAD00001006391</full_dataset_link><sample_count>29</sample_count><description>EGA dataset EGAD00001006391</description><repository>EGA</repository><title>NECC WXS</title><pubmed_abstract>In order to improve treatment selection for high grade neuroendocrine carcinomas of the cervix (NECC), we performed a comparative genomic analysis between this rare tumor type and other cervical cancer types, as well as extra-cervical neuroendocrine small cell carcinomas of the lung and bladder. We performed whole exome sequencing on fresh-frozen tissue from 15 NECCs and matched normal tissue. We then identified mutations and copy number variants using standard analysis pipelines. Published mutation tables from cervical cancers and extra-cervical small cell carcinomas were used for comparative analysis. Descriptive statistical methods were used and a two-sided threshold of P &lt; .05 was used for significance. In the NECC cohort, we detected a median of 1.7 somatic mutations per megabase (range 1.0-20.9). PIK3CA p.E545K mutations were the most frequency observed oncogenic mutation (4/15 tumors, 27%). Activating MAPK pathway mutations in KRAS (p.G12D) and GNAS (p.R201C) co-occurred in two tumors (13%). In total we identified PI3-kinase or MAPK pathway activating mutations in 67% of NECC. When compared to NECC, lung and bladder small cell carcinomas exhibited a statistically significant higher rate of coding mutations (P &lt; .001 for lung; P = .001 for bladder). Mutation of TP53 was uncommon in NECC (13%) and was more frequent in both lung (103 of 110 tumors [94%], P &lt; .001) and bladder (18 of 19 tumors [95%], P &lt; .001) small cell carcinoma. These comparative genomics data suggest that NECC may be genetically more similar to common cervical cancer subtypes than to extra-cervical small cell neuroendocrine carcinomas of the lung and bladder. These results may have implications for the selection of cytotoxic and targeted therapy regimens for this rare disease.</pubmed_abstract><pubmed_title>Comparative genomics of high grade neuroendocrine carcinoma of the cervix.</pubmed_title><pubmed_authors>Hillman R Tyler RT, Cardnell Robert R, Fujimoto Junya J, Lee Won-Chul WC, Zhang Jianjun J, Byers Lauren A LA, Ramalingam Preetha P, Leitao Mario M, Swisher Elizabeth E, Futreal P Andrew PA, Frumovitz Michael M</pubmed_authors></additional><is_claimable>false</is_claimable><name>01597d9d-b85e-43c5-b035-cb21abfeb9e1 - samples</name><description>Whole exome sequencing of neuroendocrine cervical cancer</description><dates><updated>2020-09-14 11:23:30</updated></dates><accession>EGAD00001006391</accession><cross_references><TAXONOMY>9606</TAXONOMY><pubmed>32544169</pubmed><EGA>EGAC00001001731</EGA><EGA>EGAS00001003142</EGA></cross_references></HashMap>